{"id":"NCT00490139","sponsor":"Novartis Pharmaceuticals","briefTitle":"ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D","officialTitle":"A Randomised, Multi-centre, Open-label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination in Patients With HER2/ErbB2 Positive Primary Breast Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-05-16","primaryCompletion":"2013-12-06","completion":"2021-07-01","firstPosted":"2007-06-22","resultsPosted":"2014-08-18","lastUpdate":"2025-03-21"},"enrollment":8381,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Neoplasms, Breast"],"interventions":[{"type":"DRUG","name":"Lapatinib","otherNames":["GW572016"]},{"type":"BIOLOGICAL","name":"Trastuzumab","otherNames":[]}],"arms":[{"label":"Lapatinib plus Trastuzumab","type":"EXPERIMENTAL"},{"label":"Trastuzumab followed by Lapatinib","type":"EXPERIMENTAL"},{"label":"Lapatinib","type":"EXPERIMENTAL"},{"label":"Trastuzumab","type":"ACTIVE_COMPARATOR"}],"summary":"This was a four-arm (parallel group) randomized, open-label, multicenter Phase 3 study to investigate the use of a combination of Lapatinib and Trastuzumab, a sequence of Trastuzumab followed by Lapatinib, and Lapatinib alone, compared to Trastuzumab alone in the adjuvant treatment of Human Epidermal Growth Factor Receptor 2 (HER2) positive early breast cancer.","primaryOutcome":{"measure":"Disease-Free Survival (DFS) at the Primary Analysis","timeFrame":"From randomization until the date of the first occurrence of disease recurrence, a contralateral invasive breast cancer, a second primary cancer, or death from any cause (median follow-up of 4.5 years)","effectByArm":[{"arm":"Lapatinib Plus Trastuzumab","deltaMin":1.9,"sd":null},{"arm":"Trastuzumab Followed by Lapatinib","deltaMin":1.3,"sd":null},{"arm":"Lapatinib","deltaMin":1,"sd":null},{"arm":"Trastuzumab","deltaMin":1.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG003","p":"0.048"},{"comp":"OG001 vs OG003","p":"0.610"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":9},"locations":{"siteCount":924,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Bulgaria","Canada","Chile","China","Czechia","Denmark","Estonia","France","Germany","Greece","Hong Kong","Hungary","India","Ireland","Israel","Italy","Japan","Mexico","Netherlands","New Zealand","Norway","Pakistan","Peru","Philippines","Poland","Romania","Russia","Singapore","Slovakia","Slovenia","South Africa","South Korea","Spain","Switzerland","Taiwan","Thailand","Ukraine","United Kingdom"]},"refs":{"pmids":["39613746","36050448","33765513","33152119","32203207","31240310","24395109"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":379,"n":2061},"commonTop":["DIARRHOEA","RASH","FATIGUE","ARTHRALGIA","NAUSEA"]}}